SEC Form SC 13G filed by Decibel Therapeutics Inc.
$DBTX
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/15/2023 | $7.00 → $2.00 | Outperform → Market Perform | SVB Securities |
| 12/2/2021 | $25.00 | Buy | JonesTrading |
| 11/15/2021 | $23.00 | Buy | HC Wainwright & Co. |
| 11/10/2021 | $15.00 → $14.00 | Outperform | SVB Leerink |
| 10/22/2021 | $21.00 | Outperform | Robert W. Baird |
| 10/22/2021 | $21.00 | Outperform | Baird |
NEW YORK, Aug. 12, 2023 (GLOBE NEWSWIRE) -- Western Asset Mortgage Capital Corporation (NYSE:WMC) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of WMC to AG Mortgage Investment Trust, Inc. Under the terms of the proposed merger, WMC shareholders will receive 1.5 shares of AG Mortgage Investment Trust, Inc. for each share of WMC common stocked owned and a cash payment from Angelo Gordon equal to approximately 9.99% of the aggregate per share merger consideration (not to exceed $7 million in total). If you are a WMC investor, and would like additional information about our investigation, please complete the Information R
- Activated CHORDTM clinical trial sites in U.S., U.K. and Spain and commenced patient screening activities; anticipate dosing first patient in the Phase 1/2 clinical trial in the second half of 2023 - - Received FDA Breakthrough Therapy Designation for DB-020 for protection against hearing loss associated with cisplatin chemotherapy - - Announced on August 9 definitive agreement for Regeneron Pharmaceuticals to acquire Decibel - BOSTON, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financi
Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss Decibel's lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related hearing loss, is in its first clinical trial TARRYTOWN, N.Y. and BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Decibel Therapeutics, Inc. (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced a definitive agreement for the acquisition of
- Initiated CHORD™, a global Phase 1/2 dose escalation clinical trial of lead gene therapy product candidate, DB-OTO - - Announced approval from the U.K. MHRA and Spanish AEMPS for CTAs for CHORD to expand the Phase 1/2 clinical trial to the U.K. and Spain in patients two years of age and younger - - Initiated manufacturing activities to support IND-enabling studies for our AAV.103 product candidate designed to restore hearing in individuals with mutations in the GJB2 gene - BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing
BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Matthew Kapusta to its Board of Directors. "We are pleased to welcome Matt to the Decibel Board. He is an accomplished life sciences executive who has played a key role in advancing gene therapy products from the laboratory to patients in need," said Laurence Reid, Ph.D., Chief Executive Officer at Decibel. "Matt's appointment to the Board provides us with a critical strategic perspective, as we continue to build Decibel and lead
- Received clearance from US FDA for IND and from UK MHRA for CTA to initiate CHORD™, a global Phase 1/2 dose escalation clinical trial of DB-OTO in pediatric patients - - Plan to initiate the CHORD™ trial in the First Half of 2023 - - Presented key non-clinical data at the 46th Annual ARO MidWinter Meeting supporting compelling safety profile of DB-OTO and preclinical data supporting selection of AAV.103 product candidate - BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial result
4 - Decibel Therapeutics, Inc. (0001656536) (Issuer)
4 - Decibel Therapeutics, Inc. (0001656536) (Issuer)
4 - Decibel Therapeutics, Inc. (0001656536) (Issuer)
SVB Securities downgraded Decibel Therapeutics from Outperform to Market Perform and set a new price target of $2.00 from $7.00 previously
JonesTrading initiated coverage of Decibel Therapeutics with a rating of Buy and set a new price target of $25.00
HC Wainwright & Co. initiated coverage of Decibel Therapeutics with a rating of Buy and set a new price target of $23.00
15-12G - Decibel Therapeutics, Inc. (0001656536) (Filer)
EFFECT - Decibel Therapeutics, Inc. (0001656536) (Filer)
S-8 POS - Decibel Therapeutics, Inc. (0001656536) (Filer)
SC 13G/A - Decibel Therapeutics, Inc. (0001656536) (Subject)
SC 13D/A - Decibel Therapeutics, Inc. (0001656536) (Subject)
SC 13D - Decibel Therapeutics, Inc. (0001656536) (Subject)